Granulocyte-macrophage colony-stimulating factor （GM-CSF） and T-cell responses： what we do and don＇t know

Granulocyte 巨噬细胞刺激殖民地的因素(GM-CSF ) 是一个重要造血的生长因素和有免疫力的调节的人。GM-CSF 也在各种各样的传播白血球的功能的活动有深刻效果。它被许多房间类型在收到有免疫力的刺激之上包括 T 房间，巨噬细胞， endothelial 房间和成纤维细胞生产。尽管 GM-CSF 局部地被生产，它能以一种 paracrine 方式行动到在主人防卫提高他们的功能的成员传播 neutrophils，单核白血球和淋巴细胞。最近的集中的调查为它增加树枝状的房间(DC ) 成熟和功能以及巨噬细胞活动的能力作为一个有免疫力的助手在 GM-CSF 的应用程序上被集中。在经历化疗的癌症病人对待嗜中性白血球减少症临床上被使用，在在治疗期间的爱滋病病人，并且在在骨髓移植以后的病人。有趣地， GM-CSF-deficient 老鼠的造血的系统看起来正常；最重要的变化在一些特定的 T 房间回答。尽管 GM-CSF 的分子的克隆用 T 房间的 cDNA 图书馆被执行， T 房间在激活以后生产 GM-CSF，是众所周知的，在 T 房间功能上有在由 T 房间和它的效果的生产的这 cytokine 的系统的调查的缺乏。在这篇文章，我们将在 T 房间主要集中于 GM-CSF 的免疫生物学。

Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinoma

AIM: To investigate the therapeutic efficacy and mechanisms of action of oncolytic-herpes-simplex-virus encoding granulocyte-macrophage colony-stimulating factor(HSVGM-CSF) in pancreatic carcinoma.METHODS: Tumor blocks were homogenized in a sterile grinder in saline.The homogenate was injected into the right armpit of each mouse.After vaccination,the mice were randomly assigned into four groups: a control group,a high dose HSVGM-CSFgroup [1 × 107plaque forming units(pfu)/tumor],a medium dose HSVGM-CSF group(5 × 106pfu/tumor) and a low dose HSVGM-CSF group(5 × 105pfu/tumor).After initiation of drug administration,body weights and tumor diameters were measured every 3 d.Fifteen days later,after decapitation of the animal by cervical dislocation,each tumor was isolated,weighed and stored in 10% formaldehyde solution.The drug effectiveness was evaluated according to the weight,volume and relative volume change of each tumor.Furthermore,GM-CSF protein levels in serum were assayed by enzyme-linked immunosorbent assays at 1,2,3 and 4 d after injection of HSVGM-CSF.RESULTS: Injection of the recombinant mouse HSV encoding GM-CSF resulted in a significant reduction in tumor growth compared to the control group,and dosedependent effects were observed: the relative tumor proliferation rates of the low dose,medium dose and high dose groups on 15 d after injection were 45.5%,55.2% and 65.5%,respectively.The inhibition rates of the tumor weights of the low,middle,and high dose groups were 41.4%,46.7% and 50.5%,respectively.Furthermore,the production of GM-CSF was significantly increased in the mice infected with HSVGM-CSF.The increase in the GM-CSF level was more pronounced in the high dose group compared to the other two dose groups.CONCLUSION: Our study provides the first evidence that HSVGM-CSFcould inhibit the growth of pancreatic cancer.The enhanced GM-CSF expression might be responsible for the phenomenon.

CONSTRUCTION OF EUKARYOTIC EXPRESSION VECTOR WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE

Objective: To construct the eukaryotic expression vector that express human granulocyte-macrophage colony-stimulating factor (hGM-CSF) gene for making highly express in mammalian cells. Methods: Extract totally RNA from the induced human fetal lung (HFL) cell line. HGM-CSF cDNA was obtained by reverse transcription-polymerase chain reaction (RT-PCR), and then directionally subcloned into the HindIII and EcoRI site on the pcDNA3.1 plasmid, which was controlled by the CMV promoter, to form the recombinant expressing vector pcDNA3.1-GM-CSF. Results: The PCR amplification was identified and the sequence was analyzed, the results showed that hGM-CSF was properly inserted into the vector and the sequence was correct.

Granulocyte-macrophage colony stimulating factor improves cardiac function in rabbits following myocardial infarction

Objective: To investigate the therapeutic potency of recombinant human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in a rabbit myocardial infarction model. Methods: A myocardial infarction was created by the ligation of the major ventricular branch of the left coronary artery in rabbits. After myocardial infarction, the animals were randomly assigned to GM-CSF treatment group, untreated groups and sham-operated group. The rabbits of the treated group were injected into GM-CSF by subcutaneous administration, 10 μg/kg/day, once a day for 5 days. The untreated and sham-operated group received a equal saline in the same manner as treated group. Six weeks later echocardiography and haemodynamic assessment were undertaken to assesse cardiac function. The size of the infarct region of the heart were also studied. Results: The untreated group exhibited significant higher left ventricle end-diastolic pressure, higher central venous pressure, and with significant lower mean blood pressure, lower peak first derivative of left ventricle pressure (dP/dt) than the sham group. Also, Rabbits in untreated group display significant systolic dysfunction shown by the decreased ejection fraction, diastolic dysfunction shown by increasing in the ratio of E wave to A wave (E/A), and display left ventricle enlargement. However, GS-CSF singnificantly prevented heart dysfunction, left ventricle enlargement, and reduced infarct size in treatment group. Conclusion: Administration GM-CSF after cardiac infarction can improve heart function. These findings indicate the technique may be a novel and simple therapeutic method for ischemic myocardium.

Granulocyte-macrophage colony-stimulating factor-transfected bone marrow stromal cells for the treatment of ischemic stroke

Adult, male, Sprague-Dawley rats were injected with granulocyte-macrophage colony-stimulating factor-transfected bone marrow stromal cells （GM-CSF-BMSCs） into the ischemic boundary zone at 24 hours after onset of middle cerebral artery occlusion. Results showed reduced infarct volume, decreased number of apoptotic cells, improved neurological functions, increased angiogenic factor expression, and increased vascular density in the ischemic boundary zone in rats that underwent GM-CSF-BMSCs transplantation compared with the BMSCs group. Experimental findings suggested that GM-CSF-BMSCs could serve as a potential therapeutic strategy for ischemic stroke and are superior to BMSCs alone.

EFFECTS OF GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR GENE ENCODED VACCINIA VIRUS VECTOR ON MURINE PULMONARY METASTATIC MELANOMA

A recombinant vaccinia virus expressing murine granulocyte-macrophage colony-stimulating factor (VVGM-CSF) was tested for its antitumor activity.Murine pulmonary metastasis was established by injecting 20×10~5 B16F10 melanoma cells into the tail vein of C57BL/6 mice. Three days after B16F10 inoculation,WGM-CSF or VVTK, a thymidine kinase gene deficient control vaccinia virus, were injected intraperitoneally twice weekly for 2 weeks. Two weeks later, the mice were sacrificed and pulmonary metastasis fool counted.The results demonstrated that VVGM-CSF treatment significantly decreased the number of pulmonary metastasis and prolonged the survival time of tumorbearing mice. Cytotoxic and phagocytic activities of the peritoncal macrophages were found to be markedly elevated in mice treated with WGM-CSF. Nitric oxide released from the macrophages was also found to be increased. These data, together with our other results,strongly demonstrated that continuous secretion of GMCSF and activation of macrophages might pal-tially explain the therapeutic effects of VVGM-CSF on murine pulmonary metastasis.

金刚藤胶囊联合桂枝茯苓胶囊治疗慢性盆腔炎的疗效及对血清GM-CSF、MMP-2水平的影响

【目的】分析金刚藤胶囊联合桂枝茯苓胶囊治疗湿热瘀结型慢性盆腔炎的疗效及对血清粒细胞-巨噬细胞集落刺激因子(GM-CSF)、基质金属蛋白酶2(MMP-2)水平的影响。【方法】将90例湿热瘀结型慢性盆腔炎患者随机分为联合组和单药组,每组各45例。单药组患者给予桂枝茯苓胶囊治疗,联合组患者在单药组的基础上联合金刚藤胶囊治疗,疗程为2周并随访1个月。观察2组患者治疗前后中医证候积分和血清GM-CSF、MMP-2水平的变化情况,比较2组患者的临床疗效、症状缓解时间、疾病复发和不良反应发生情况。【结果】(1)疗效方面,治疗2周后,联合组的总有效率为93.33%(42/45),单药组为66.67%(30/45),组间比较,联合组的疗效明显优于单药组(P<0.01)。(2)中医证候积分方面,治疗后,2组患者的下腹疼痛、腰骶疼痛、带下量多、月经量多、经行腹痛、神疲乏力等各项中医证候积分均较治疗前明显降低(P<0.05),且联合组对各项中医证候积分的降低幅度均明显优于单药组(P<0.05)。(3)症状缓解时间方面,联合组患者治疗后的白带恢复正常时间、下腹坠胀和腹痛缓解时间均较单药组明显缩短(P<0.01)。(4)血清学指标方面,治疗后,2组患者的血清GM-CSF、MMP-2水平均较治疗前明显降低(P<0.05),且联合组对血清GM-CSF、MMP-2水平的降低幅度均明显优于单药组(P<0.05或P<0.01)。(5)疾病复发和不良反应方面,联合组的复发率和不良反应发生率分别为11.11%(5/45)、13.33%(6/45),均明显低于单药组的35.56%(16/45),差异均有统计学意义(P<0.05或P<0.01)。【结论】金刚藤胶囊联合桂枝茯苓胶囊治疗,可以显著提高湿热瘀结型慢性盆腔炎的临床疗效,有效缩短症状缓解时间,降低血清GM-CSF、MMP-2水平。

血清GM-CSF、IGF-1联合检测在妊娠期糖尿病患者不良妊娠结局诊断中的价值

目的:分析血清粒细胞-巨噬细胞集落刺激因子(GM-CSF)、胰岛素样生长因子-1(IGF-1)联合检测在妊娠期糖尿病(GDM)患者不良妊娠结局诊断中的价值。方法:选取2021年6月至2023年3月该院收治的83例GDM患者设为研究组,根据妊娠结局将其分为不良结局患者(n=24)和良好结局患者(n=59),另选取同期160名健康孕妇作为对照组,比较两组及不同妊娠结局GDM患者血清GM-CSF、IGF-1水平,绘制受试者工作特征(ROC)曲线,分析血清GM-CSF、IGF-1单项及联合检测在GDM患者不良妊娠结局诊断中的价值。结果:研究组血清IGF-1水平低于对照组,GM-CSF水平高于对照组,差异均有统计学意义(P<0.05);不良结局患者IGF-1水平低于良好结局患者,GM-CSF水平高于良好结局患者,差异均有统计学意义(P<0.05);ROC曲线分析结果显示,血清IGF-1、GM-CSF单项及联合检测诊断GDM患者不良妊娠结局的曲线下面积分别为0.821、0.822、0.912,均具有一定诊断价值,且联合检测诊断价值最高。结论:血清GM-CSF、IGF-1联合检测在GDM患者不良娠结局诊断中的价值高于二者单项检测。

IMMUNOHISTOCHEMICAL OBSERVATION OF MACROPHAGE COLONY STIMULATING FACTOR AND ITS RECEPTOR IN BREAST CANCER AND HEPATOMA TISSUES

Objective: To study the potential role of cellular macrophage colony-stimulating factor (cM-CSF) and cellular macrophage colony-stimulating factor receptor (cM-CSF-R) with breast cancer and hepatoma and search the way for clinical application. Methods: Frozen surgical specimens from 48 breast cancer patients, including 29 cases of histological grade II and 19 eases of grade III, and 16 hepatoma patients were investigated by Avidin Biotin Complex (ABC) immunohistochemical assay with anti-M-CSF monoclonal antibody (Mab) and anti-M-CSF-R Mab. Pathohistological examination was performed as well. Results: cM-CSF and cM-CSF-R were detected in tested specimens. The expression levels of cM-CSF and cM-CSF-R in grade III group were higher than in grade II group and more higher than control group hyperplasia of breast. Hepatoma tissues also showed higher expression level of cM-CSF and cM-CSF-R than normal adult and fetal liver. Conclusion: Breast cancer and hepatoma tissues presented higher expression levels of cM-CSF and cM-CSF-R than control and expression level might be related with tumor’s process.

CO-EXPRESSION OF MACROPHAGE COLONY-STIMULATING FACTOR WITH ITS RECEPTOR IN HUMAN HEPATOMA CELLS AND ITS POTENTIAL ROLES

Objective: To investigate the potential role of macrophage colony-stimulating factor (M-CSF) and macrophage colony-stimulating factor receptor (M-CSF-R) on the growth of human hepatoma cells. Methods: Specimens of different origin, including tissues of human hepatocellular carcinoma (HCC), human fetal liver (FL) and normal liver (NL), the hepatoma cell lines, as well as the peripheral blood mononuclear cells (PBMC) from patients with HCC or liver metastatic tumor (LMT), were used to detect the expression levels of M-CSF and M-CSF-R by ABC immunohistochemistry staining and reverse transcription polymerase chain reaction methods the expression levels of M-CSF and M-CSF-R. Influence of monoclonal antibody against M-CSF (B5) or M-CSF-R (RE2) on proliferation ability of hepatoma cell linesin vitro was also studied. Results: The results showed that hepatoma tissues produced elevated levels of both M-CSF and M-CSF-R compared with those of fetal liver (P<0.001). The M-CSF/M-CSF-R expression levels of PBMC from hepatoma patients were higher than those of LMT patients (P<0.01,P<0.05) and the normal people (P<0.001). The hepatoma cell lines showed strong positive for M-CSF and M-CSF-R production. Both B5 and RE2 displayed a dose-dependent inhibitory effect on the growth and proliferation of hepatoma cells. Conclusion: The study indicates a co-expression model for M-CSF-R in hepatoma cells, suggesting an involvement of M-CSF/M-CSF-R in growth signaling of those malignant cells. The M-CSF/M-CSF-R seems to function through an autonomy mechanism in human hepatoma.

Mobilization of Peripheral Blood Stem Cells Using Regimen Combining Docetaxel with Granulocyte Colony-stimulating Factor in Breast Cancer Patients

Objective：To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor（G-CSF） in breast cancer patients.Methods：A total of 57 breast cancer patients were treated with docetaxel 120 mg/m2.When the white blood cell（WBC） count decreased to 1.0×109/L,patients were given G-CSF 5-g/kg daily by subcutaneous injection until the end of apheresis.Peripheral blood mononuclear cells（MNC） were isolated by Cobe Spectra Apheresis System.The percentage of CD34＋ cell was assayed by flow cytometry.Results：At a median 6 of days（range 3-8） after the administration of docetaxel,the median WBC count decreased to 1.08×109/L（range 0.20-2.31）.The median duration of G-CSF mobilization was 3 days（range 2-7）.The MNC collection was conducted 8-12 days（median 10 days） after docetaxel treatment.The median MNC was 5.35×108/kg（range 0.59-14.07）,the median CD34＋ cell count was 2.43×106/kg（range 0.16-16.69）.The CD34＋ cell count was higher than 1.00×106/kg in 47 of 57 cases（82.46%） and higher than 2.00×106/kg in 36 cases（63.16%）.The CD34＋ cell count was higher than 2.00×106/kg in 27 collections（23.68%）.The MNC count and the CD34＋ cell count were correlated with the bottom of WBC after docetaxel chemotherapy（r=0.364,0.502,P=0.005,0.000）.The CD34＋ cell count was correlated with the MNC count（r=0.597,P=0.000）.The mobilization and apheresis were well tolerated in all patients.Mild perioral numbness and numbness of hand or feet were observed in 3 cases.No serious adverse events were reported.Conclusion：Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancer patients.

ENHANCEMENT OF NIH3T3 CELL PROLIFERATION BY EXPRESSING MACROPHAGE COLONY STIMULATING FACTOR IN NUCLEI

Objective: To explore the effects of nuclear M-CSF on the process of tumorigenesis. Methods: Functional part of M-CSF cDNA was inserted into an eukaryotic expression plasmid pCMV/myc/nuc, which can add three NLS to the C-terminal of the expressed protein and direct the protein into the cell nuclei. The constructed plasmid was transferred into NIH3T3 cells and the cell clones were selected by G-418 selection. Cell clones stable expressing target protein were identified by RT-PCR, ABC immunohistochemistry assayand Western blot. Cell growth kinetics analyses throughgrowth curves, cell doubling time, MTT test and anti-sense oligodeoxynucleotide (ASODN) inhibiting cell growth testwere performed to identify cells proliferation potential.Results: The transfected cells showed elevated proliferation potential over the control cells. Conclusion: Abnormalappearance of M-CSF in nucleus could enhance cellproliferation, which suggests that cytokine isoforms within cell nucleus might play transcription factor-like role.

Granulocyte Colony-Stimulating Factor Enhances the Anticancer Effects of Cisplatin against Lung Cancer by Promoting Angiogenesis

The G-CSF is used as a therapeutic drug of the febrile neutropenia in lung cancer chemotherapy, however, there were few reports that showed the effects of combination effects of G-CSF and anticancer drugs against lung cancer. In the present study, we investigated the effects of G-CSF and the combination effects of G-CSF and cisplatin on lung cancer growth. We investigated the effect of G-CSF against the LL-2 and KLN-205 cells by MTT assay and tried to detect the G-CSF receptor by RT-PCR. Next, to analyze the G-CSF effects in vivo, we transplanted the LL-2 into C57BL/6 mice, intraperitoneally administered G-CSF (30 micro/kg/day) with or without cisplatin (5 mg/kg), measured the tumor size and analyzed pathologically by HE and immunostaining. In vitro analyses, G-CSF showed no effects in LL-2 and KLN-205 cells, and RT-PCR revealed no G-CSF receptor mRNA. In vivo analyses, G-CSF alone did not significantly suppress tumor growth. However, concurrent G-CSF administration with cisplatin significantly enhanced the tumor suppressing effect of cisplatin in early stage of tumor growth. The analysis data of vWF immunostaining indicated that the neovascularization in the peripheral region of the tumors was more enhanced in G-CSF treatment mice. ELISA assay revealed that G-CSF did not influence the serum concentration of TNF-alpha and IL-12 in tumor-bearing mice. This study suggests that concurrent (combination) administration of cisplatin with G-CSF is a safe and effective method for enhancing anticancer effects and reducing chemotherapeutic agent-induced myelosuppression.

rhGM⁃CSF预防非小细胞肺癌放疗所致急性放射性食管炎的效果观察

目的探讨注射用重组人粒细胞⁃巨噬细胞集落刺激因子(rhGM⁃CSF)预防非小细胞肺癌(NSCLC)放疗所致急性放射性食管炎的效果。方法选取2016年6月至2020年10月医院收治的168例拟接受放疗的NSCLC患者为研究对象,以随机数字表法分为对照组(n=84)和研究组(n=84)。对照组采用三维适形放疗联合化疗进行治疗,研究组在对照组的基础上采用rhGM⁃CSF治疗,2组均治疗2~6个周期。比较2组治疗前后免疫功能、生活质量核心问卷(QLQ⁃C30)评分,比较2组治疗后放射性食管炎发生情况以及放射性食管炎视觉模拟量表(VAS)评分。结果治疗后,2组CD4+、CD3+、CD16+CD56+水平均升高(P<0.05),研究组高于对照组(P<0.05);治疗后,2组放射性食管炎分级等级差异有统计学意义(P<0.05),且研究组3~4级放射性食管炎发生率低于对照组(P<0.05);2组放射性食管炎患者VAS评分均降低(P<0.05),研究组放射性食管炎患者VAS评分低于对照组(P<0.05);2组QLQ⁃C30评分均降低(P<0.05),研究组低于对照组(P<0.05)。结论rhGM⁃CSF联合三维适形放疗用于治疗NSCLC患者,可改善患者的免疫功能,提高患者的生活质量,减少3~4级放射性食管炎发生率,减轻NSCLC患者经三维适形放疗所致放射性食管炎患者疼痛。

PRP凝胶与rhGM-CSF凝胶治疗慢性难愈性创面的效果及对创面修复因子的影响

目的比较自体富血小板血浆(PRP)凝胶与重组人粒细胞巨噬细胞集落刺激因子(rhGM-CSF)凝胶治疗慢性难愈性创面的效果及对创面修复因子的影响。方法将80例慢性难愈性创面患者分为PRP组和rhGM-CSF组,各40例。在外科常规治疗基础上,PRP组采用PRP凝胶治疗,rhGM-CSF组采用rhGM-CSF凝胶治疗。比较两组患者创面完全愈合时间,治疗2周后创面愈合率、感染控制水平,治疗前后创面修复因子[血管内皮生长因子(VEGF)、血小板衍生生长因子(PDGF)、碱性成纤维细胞生长因子(bFGF)、表皮生长因子(EGF)]表达量、疼痛视觉模拟量表(VAS)评分。记录两组患者治疗过程中不良反应的发生情况。结果PRP组创面完全愈合时间短于rhGM-CSF组(P<0.05)。治疗2周后,PRP组患者创面愈合率高于rhGM-CSF组;两组患者疼痛VAS评分、白细胞计数及血清C反应蛋白水平均低于治疗前,创面VEGF、PDGF、bFGF、EGF表达量均较治疗前升高,且PRP组患者上述指标均优于rhGM-CSF组(均P<0.05)。两组患者治疗前后的创面细菌培养阳性情况差异无统计学意义(P>0.05)。治疗过程中PRP组无不良反应发生,rhGM-CSF组共出现3例不良反应,两组不良反应总发生率差异无统计学意义(P>0.05)。结论PRP凝胶与rhGM-CSF凝胶对慢性难愈性创面患者的创面愈合情况、疼痛、感染水平等均具有改善作用,而PRP凝胶上述效果优于rhGM-CSF凝胶。

rhG-CSF在治疗儿童化疗性口腔黏膜炎中的应用研究

目的探究重组人粒细胞集落刺激因子(recombinant human granulocyte-colony stimulating factor,rhG-CSF)在治疗儿童化疗性口腔黏膜炎中的应用效果。方法选取2020年1月至2022年6月于笔者医院肿瘤外科化疗的60例化疗性口腔黏膜炎患儿,按随机数字表法分为两组,每组30例。对照组采取生理盐水口腔护理,实验组采取rhG-CSF口腔护理。比较两组患儿干预效果、口腔黏膜炎分度、生存质量[健康状况调查简表(36-item short—form,SF-36)]、患儿家长护理满意度。结果实验组总有效率较对照组高,差异有统计学意义(P<0.05)。干预5d,实验组患儿口腔黏膜炎分度结果优于对照组,差异有统计学意义(P<0.05)。干预5d,两组患儿SF-36评分较干预前高,实验组较对照组高,差异有统计学意义(P<0.05)。实验组患儿家长满意度较对照组高,差异有统计学意义(P<0.05)。结论rhG-CSF口腔护理可有效提高儿童化疗性口腔黏膜炎的干预效果,减轻口腔黏膜炎分度,改善患儿生存质量,提高患儿家长护理满意度。

GM-CSF在神经退行性疾病炎性反应过程中的作用

神经退行性疾病是一种慢性进行性疾病,主要影响中枢神经系统(CNS)。疾病的特征是神经元结构和功能逐渐丧失,且与炎症过程密切相关。中枢神经系统中的炎症被称为神经炎症,与多种神经退行性疾病有关,如阿尔茨海默病(AD)、帕金森病(PD)和多发性硬化症(MS)等。粒细胞-巨噬细胞集落刺激因子(GM-CSF)作为一种促炎细胞因子,在慢性炎症发展中扮演着关键的角色,其被认为对中枢神经退行性疾病的发生和进展具有广泛的影响。本文综述了GM-CSF在神经退行性疾病中的炎性反应过程,为进一步探索GM-CSF在相关治疗中的潜在作用提供了临床依据,对于神经退行性疾病的分子机制阐明将为抗神经退行性疾病炎性反应提供有效的靶点。

参芪归血汤配方颗粒联合化疗对SQBD型晚期NSCLC患者血清GM-CSF、G-CSF及免疫指标的影响

目的研究参芪归血汤配方颗粒联合化疗对气血亏虚证(SQBD)型晚期NSCLC患者血清GM-CSF、G-CSF及免疫指标水平的影响。方法依据治疗方案,随机选出2020年7月至2021年12月符合纳入标准且仅给予常规NP化疗方案的SQBD型晚期NSCLC患者42例为对照组,选出同期给予相同化疗方案并加服参芪归血汤配方颗粒的42例为观察组。比较两组外周血细胞参数水平、免疫指标参数水平、肿瘤标志物水平、血清GM-CSF和G-CSF水平,KPS评分、不良反应发生率和化疗疗效。结果观察组WBC、HGB、PLT和Neu参数水平均显著高于对照组(第8、22、36天组间比较)(P<0.05);研究后,观察组免疫指标参数水平、肿瘤标志物水平降低幅度、血清GM-CSF和G-CSF水平、KPS评分及其改稳率等方面显著优于对照组(P<0.05),观察组WBC降低、HGB降低、Neu减少、恶心呕吐和便秘等不良反应发生率较对照组明显减少(P<0.05);观察组化疗总有效率62.50%显著大于对照组39.02%(P<0.05)。结论联用参芪归血汤配方颗粒的给药方案对SQBD型晚期NSCLC患者化疗更具优势,能从补气、养血两个方面,改善患者SQBD症状,对提升患者生活质量、降低部分不良反应发生率、提高临床化疗疗效有帮助,其机制与参芪归血汤配方颗粒能有效调节患者血清中GM-CSF、G-CSF及免疫指标水平有关。

血府逐瘀胶囊联合阿奇霉素序贯疗法治疗慢性盆腔炎的效果及对抗炎-促炎因子表达、TGF-β_(1)、GM-CSF水平的影响

目的探讨血府逐瘀胶囊联合阿奇霉素序贯疗法治疗慢性盆腔炎(CPID)的效果及对抗炎-促炎因子表达、转化生长因子-β_(1)(TGF-β_(1))、粒细胞-巨噬细胞集落刺激因子(GM-CSF)水平的影响。方法选取2018年9月至2021年3月收治的106例CPID患者为研究对象,以随机数字表法将其分为对照组与观察组,各53例。对照组采用阿奇霉素序贯疗法,观察组在对照组基础上加用血府逐瘀胶囊。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的白细胞介素-6(IL-6)、白细胞介素-10(IL-10)及白细胞介素-17(IL-17)水平比较,差异无统计学意义(P>0.05);治疗后,观察组的IL-6及IL-17水平低于对照组,IL-10水平高于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的TGF-β_(1)、GM-CSF水平比较,差异无统计学意义(P>0.05);治疗后,观察组的TGF-β_(1)、GM-CSF水平低于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的生理职能、精神健康、躯体疼痛及总体健康评分比较,差异无统计学意义(P>0.05);治疗后,观察组的生理职能、精神健康、躯体疼痛及总体健康评分高于对照组,差异具有统计学意义(P<0.05)。结论血府逐瘀胶囊联合阿奇霉素序贯疗法治疗CPID效果满意,可调节抗炎-促炎因子表达,改善TGF-β_(1)、GM-CSF水平,提高患者的生活质量,值得临床推广应用。

rhGM-CSF凝胶联合磺胺嘧啶银对面部深Ⅱ度烧伤创面愈合质量的影响

目的:探讨重组人粒细胞巨噬细胞集落刺激因子(Recombinant human granulocyte macrophage colony stimulating factor,rhGM-CSF)联合磺胺嘧啶银治疗面部深Ⅱ度烧伤的疗效。方法:选择2016年6月-2021年11月笔者医院收治的96例面部深Ⅱ度烧伤患者,采用随机数表法分为观察组和对照组各48例,对照组给予磺胺嘧啶银霜治疗,观察组给予磺胺嘧啶银霜+rhGM-CSF凝胶治疗,比较两组创面愈合相关指标及美学效果。结果:观察组创面结痂时间、痂皮基本溶解时间及创面完全愈合时间均短于对照组(P<0.05),治疗后各时间点疼痛评分均低于对照组(P<0.05);治疗后,两组创面细菌培养阳性率均降低,但组间比较差异无统计学意义(P>0.05);治疗后1、2周,两组血清血管内皮生长因子(Vascular endothelial growth factor,VEGF)、表皮生长因子(Epidermal growth factor,EGF)、转化生长因子β1(Transforming growth factor-β1,TGF-β1)水平均高于治疗前,且观察组高于对照组(P<0.05);治疗3周后,观察组创面美学效果各评分及总分均明显高于对照组(P<0.05);两组并发症发生率比较差异无统计学意义(P>0.05)。结论:对面部深Ⅱ度烧伤患者采用rhGM-CSF凝胶与磺胺嘧啶银联合治疗,可有效促进患者创面愈合、降低疼痛程度,提高血管生长因子水平,美学效果好,值得在临床推广应用。